Loading...
XSHG
600572
Market cap1.52bUSD
Jul 10, Last price  
4.12CNY
1D
1.23%
1Q
-6.79%
Jan 2017
-43.64%
IPO
262.56%
Name

Zhejiang CONBA Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600572 chart
P/E
22.05
P/S
1.62
EPS
0.19
Div Yield, %
3.69%
Shrs. gr., 5y
-0.17%
Rev. gr., 5y
1.84%
Revenues
6.47b
-0.64%
1,279,345,5071,237,594,2591,094,915,7491,406,541,5781,891,949,1352,259,941,2552,733,691,1962,924,158,4583,581,615,5465,301,970,1416,020,371,0535,293,966,7777,018,120,0576,768,292,9195,909,017,0196,568,185,3416,000,443,3936,732,797,0366,515,163,4356,473,433,792
Net income
474m
-23.79%
84,410,950106,131,69791,973,561101,216,594194,968,591280,227,613295,713,141417,369,669552,347,432440,371,506441,069,521711,116,248815,163,095-345,627,840453,301,7442,017,463,211358,119,423591,572,945622,417,035474,363,102
CFO
943m
-6.91%
71,201,52579,984,20398,555,327153,393,899125,929,206188,357,115245,758,214235,355,284617,434,215831,260,038969,706,133712,266,959545,776,464925,500,5391,249,699,895889,935,2381,155,481,693898,640,7241,012,529,326942,609,399
Dividend
Jun 25, 20250.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang CONBA Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd., is headquartered in Hangzhou, China. Established in 1969, and formerly known as Lanxi Yunshan Pharmaceutical Factory until its name change in October 1999, the company specializes in the research, development, manufacturing, and distribution of traditional Chinese medicines and botanical products across China. Its broad portfolio extends to include chemical pharmaceuticals, proprietary Chinese medicines, vision care products, dietary supplements, general health supplies, everyday wellness goods, food items, and various personal care products.
URL
http://www.conbapharm.com/
IPO date
Apr 12, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT